METTL3-mediated m6A modification stabilizes YOD1 to promote Bcl-xL-dependent enzalutamide resistance in prostate cancer

Resistance to enzalutamide remains a major challenge in advanced prostate cancer, but the mechanisms linking epitranscriptomic regulation to apoptotic escape remain incompletely understood. By integrating MeRIP-seq and RNA-seq analyses of parental and enzalutamide-resistant prostate cancer cells, we identified the deubiquitinase YOD1 as a candidate mediator of resistance. YOD1 depletion enhanced enzalutamide-induced apoptosis and suppressed resistant tumor growth in vitro and in vivo. Mechanistically, METTL3-dependent m6A modification at A1360 promoted the association of YOD1 mRNA with IGF2BP2, thereby enhancing transcript stability and YOD1 expression. YOD1 associated with Bcl-xL and limited its K48-linked ubiquitination and proteasomal degradation. Catalytic-mutant and genetic rescue experiments supported the requirement for YOD1 deubiquitinase activity and positioned Bcl-xL as a functional downstream effector. Pharmacological inhibition of Bcl-xL with A-1,155,463 enhanced the response to enzalutamide in cellular and resistant xenograft models. In addition, immunohistochemical analysis of prostate cancer specimens revealed positive associations among METTL3, YOD1 and Bcl-xL protein abundance. Together, these findings support an m6A-deubiquitinase-Bcl-xL regulatory cascade that contributes to apoptotic resistance during enzalutamide treatment. This pathway may represent a potential therapeutic vulnerability, although its clinical relevance requires further validation.

Authors

Institutions

Publication Details

Journal
Cellular and Molecular Life Sciences
Published
2026-11-16
DOI
https://doi.org/10.1007/s00018-026-06518-1
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

METTL3-mediated m6A modification stabilizes YOD1 to promote Bcl-xL-dependent enzalutamide resistance in prostate cancer

Yueming Chen, Lu Chen, 杨晓群, Haozhuo Song et al.
2 links
Cellular and Molecular Life Sciences
RNA modifications and cancer
article

METTL3-mediated m6A modification stabilizes YOD1 to promote Bcl-xL-dependent enzalutamide resistance in prostate cancer

Yueming Chen, Lu Chen, 杨晓群, Haozhuo Song, Hai Huang, Danfeng Xu, Da Huang, Guixin Zhang, Zeping Chen, Zixian Wang
article en

Abstract

Resistance to enzalutamide remains a major challenge in advanced prostate cancer, but the mechanisms linking epitranscriptomic regulation to apoptotic escape remain incompletely understood. By integrating MeRIP-seq and RNA-seq analyses of parental and enzalutamide-resistant prostate cancer cells, we identified the deubiquitinase YOD1 as a candidate mediator of resistance. YOD1 depletion enhanced enzalutamide-induced apoptosis and suppressed resistant tumor growth in vitro and in vivo. Mechanistically, METTL3-dependent m6A modification at A1360 promoted the association of YOD1 mRNA with IGF2BP2, thereby enhancing transcript stability and YOD1 expression. YOD1 associated with Bcl-xL and limited its K48-linked ubiquitination and proteasomal degradation. Catalytic-mutant and genetic rescue experiments supported the requirement for YOD1 deubiquitinase activity and positioned Bcl-xL as a functional downstream effector. Pharmacological inhibition of Bcl-xL with A-1,155,463 enhanced the response to enzalutamide in cellular and resistant xenograft models. In addition, immunohistochemical analysis of prostate cancer specimens revealed positive associations among METTL3, YOD1 and Bcl-xL protein abundance. Together, these findings support an m6A-deubiquitinase-Bcl-xL regulatory cascade that contributes to apoptotic resistance during enzalutamide treatment. This pathway may represent a potential therapeutic vulnerability, although its clinical relevance requires further validation.

Cellular and Molecular Life Sciences
Shanghai Jiao Tong University (CN), Ruijin Hospital (CN), Sir Run Run Shaw Hospital (CN), Shanghai Institute of Immunology (CN), Zhejiang University (CN)
National Natural Science Foundation of China, Shanghai Jiao Tong University, School of Medicine, Shanghai Jiao Tong University
Good health and well-being
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon